A statistical model to estimate lung density (LD) utilizing oscillometry (OS), biometrics (BM), patient reported outcomes (PRO) and pulmonary function tests (PFT) Source: International Congress 2016 – The future of lung function is beginning now Year: 2016
Prevalence rates of symptoms and diagnoses of chronic bronchitis (CB), emphysema (E) and asthma (A), with or without airflow obstruction (AO), in two Italian general population samples Source: Eur Respir J 2005; 26: Suppl. 49, 595s Year: 2005
The impact of the three GOLD severity classifications of COPD (2001, 2011 and 2017) in the same population of patients. Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers Year: 2017
“Novel therapies for severe asthma in children and adults.” Vasiliki Delimpoura, Clementine Bostantzoglou, Norrice Liu, Raffaella Nenna. Breathe 2018; 14: 59–62. Source: Breathe, 14 (2) 165; 10.1183/20734735.518917 Year: 2018
Chronic alcoholics[scquote] (CA) knowledge (KN) and social stigmatisation (ST) regarding tuberculosis (TB) Source: Eur Respir J 2001; 18: Suppl. 33, 322s Year: 2001
Bone and joint tuberculosis in Bradford: a 6 year review (1999-2004) Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005
Asthma control (AC) 1 year after pulmonary rehabilitation (PR) Source: Annual Congress 2011 - Challenges in rehabilitation: some old dilemmas revisited with some solutions? Year: 2011
Mometasone/indacaterol (MF/IND) and mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) and FLU/SAL+tiotropium (TIO) in patients with inadequately controlled asthma: data from the PLATINUM program Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013
COPD (C) and asthma (A) comorbidities in Italian primary care Source: Annual Congress 2010 - Comorbidity in obstructive airway disease Year: 2010
Asthma treatment: influence of psychology rehabilitation (PR) on the course of disease (CD), psychological status (PS) and the smoking cessation rate (SCR) Source: Eur Respir J 2005; 26: Suppl. 49, 487s Year: 2005
Anti-inflammatory activity of Erespal (Fenspirid, Servie, France) in COPD patients Source: Annual Congress 2007 - Treatment of COPD Year: 2007
Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level Source: Annual Congress 2012 - COPD exacerbation Year: 2012
Association between asthma exacerbations and air pollution in Badalona (Barcelona), (2008-2016). Source: International Congress 2018 – Asthma and drugs Year: 2018
CAT in COPD phenotypes (POPE study) Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015
Cardiovascular diseases (CVD), arterial hypertension (AH) and diabetes mellitus (DM) in a cohort of 609 COPD patients: Associations with the new GOLD classification 2011 Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations Year: 2013